Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo controlled, single and multiple dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of NMD670 in male and female healthy subjects and patients with myasthenia gravis

Next Previous
X
Search
Trial Profile

A randomised, double-blind, placebo controlled, single and multiple dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of NMD670 in male and female healthy subjects and patients with myasthenia gravis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bromophenoxyazole propanoic acid (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms CHDR1948
  • Sponsors NMD Pharma

    • Most Recent Events

    • 21 Mar 2024 According to a NMD Pharma media release, the company published positive Phase 1/2a data in the journal Science Translational Medicine.
    • 03 Oct 2023 According to a NMD Pharma media release, data from this study will be presented at the 28th International Annual Congress of the World Muscle Society taking place at the Charleston Convention Center in Charleston, South Carolina, US from 3-7 October.
    • 08 Sep 2023 According to a NMD Pharma media release, company will be hosting a satellite symposium and presenting new data from this clinical trial at the conference,The 148th Annual Meeting of the American Neurological Association taking place from 9-12 September, Philadelphia, US.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top